Jan 12 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in combination with chemoradiotherapy to treat patients with a type of advanced cervical cancer. (Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)